Neoplasms

All Conditions

Symptoms and General Pathology

Mouth and Tooth Diseases

Ear, Nose, and Throat Diseases

Rare Diseases

Carcinoma

Neoplasm Metastasis

Nasopharyngeal Carcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Neoplastic Processes

Nasopharyngeal Neoplasms

Pharyngeal Neoplasms

Otorhinolaryngologic Neoplasms

Head and Neck Neoplasms

Nasopharyngeal Diseases

Pharyngeal Diseases

Stomatognathic Diseases

Otorhinolaryngologic Diseases

Antineoplastic Agents

All Drugs and Chemicals

Gemcitabine

Capecitabine

Paclitaxel

Pembrolizumab

Tislelizumab

Albumin-Bound Paclitaxel

Cisplatin

Antineoplastic Agents, Immunological

Gemcitabine combined with cisplatin regimen combined with Tislelizumab

cisplatin, nab-paclitaxel and capecitabine regimen combined with Tislelizumab

GP combined with Tislelizumab

TPC combined with Tislelizumab

Yanqun Xiang

Guoying Liu

Yanqun Xiang, MD

Weixiong Xia, MD

This is a prospective, open-label phase III clinical trial evaluating the efficacy and safety of the GP（Gemcitabine combined with cisplatin） regimen in combination with Tislelizumab versus the TPC（cisplatin, nab-paclitaxel and capecitabine）regimen in combination with Tislelizumab for the first-line treatment of Nasopharyngeal Carcinoma patients With Bone Metastasis.

This study aims to evaluate the efficacy and safety of the GP regimen combined with Tislelizumab compared to the TPC regimen combined with Tislelizumab in the treatment of advanced first-line bone metastatic nasopharyngeal carcinoma patients in high-risk nasopharyngeal carcinoma areas through a prospective, open-label phase III clinical trial.

Active Comparator:Drug:GP（Gemcitabine combined with cisplatin）regimen combined with Tislelizumab Experimental:Drug：TPC（cisplatin, nab-paclitaxel and capecitabine）regimen combined with Tislelizumab

Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.

A Randomized, Controlled, Multicenter Clinical Study Comparing the Efficacy of Pembrolizumab in Combination With Nab-TPC Regimen Versus the GP Regimen in the First-Line Treatment of Nasopharyngeal Carcinoma With Bone Metastases.

The diagnosis, treatment regimen, toxicity and followup data will be shared once every year through email, phone or meeting.

XIANG YANQUN

Professor

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.	NCT06383780	Nasopharyngeal ...	GP combined wit... TPC combined wi...	18 Years -	Sun Yat-sen University
Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.	NCT06383780	Nasopharyngeal ...	GP combined wit... TPC combined wi...	18 Years -	Sun Yat-sen University

Spots Global Cancer Trial Database for nasopharyngeal carcinoma with bone metastasis